Nadolol

Nadolol

Clinical data
Trade names	Corgard
AHFS/Drugs.com	Monograph
MedlinePlus	a682666
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	C07AA12 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	30%
Metabolism	Nil
Biological half-life	14-24 hours
Excretion	Renal and fecal (unchanged)
Identifiers
IUPAC name * rel-(2R,3S)-5-{[(2R)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-1,2,3,4-tetrahydronaphthalene-2,3-diol (2R*,3S*)-5-{[(2R*)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-1,2,3,4-tetrahydronaphthalene-2,3-diol
CAS Number	42200-33-9 Y
PubChem (CID)	39147
IUPHAR/BPS	554
DrugBank	DB01203 Y
ChemSpider	35815 Y
UNII	FEN504330V Y
KEGG	D00432 Y
ChEMBL	CHEMBL649 Y
ECHA InfoCard	100.050.625
Chemical and physical data
Formula	C17H27NO4
Molar mass	309.401 g/mol
3D model (Jmol)	Interactive image
SMILES OC(CNC(C)(C)C)COc1cccc2c1C[C@H](O)[C@H](O)C2
InChI InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1 Y Key:VWPOSFSPZNDTMJ-UCWKZMIHSA-N Y

Nadolol (Corgard) is a non-selective beta blocker used in the treatment of high blood pressure and chest pain. Additionally, it is often prescribed in the treatment of atrial fibrillation, migraine headaches, and complications of cirrhosis.

Nadolol is a mixture of stereoisomers. It is polar and hydrophilic, with low lipid solubility.

Nadolol is used to treat hypertension and for long-term treatment of angina pectoris and is approved by the FDA for these purposes.

It is regularly used off-label for control of heart rate in people with atrial fibrillation, prevention of migraine headaches; prevention of bleeding veins in people with portal hypertension caused by cirrhosis; and to treat people with high levels of thyroid hormone.

Nadolol is one of the preferred beta-blockers in the management of patients with LQTS for shortening of the QT interval and prevention of ventricular arrhythmia. It is more efficacious than metoprolol in the prevention of breakthrough cardiac events while on therapy and is equivalent to propranolol. Nadolol has the advantage of once daily dosing and thus improved patient compliance. For patients with decreased kidney function, nadolol may be dosed less often. It has also been found to be useful (off-label) for several neurological disorders such as the prevention of migraine attacks,attention deficit/hyperactivity disorder(ADHD) and its use has been explored as a treatment for essential tremor and Parkinson's disease but neither is well established.